On 21 January 2019 in Paris, Sanofi, Servier, Medicen Paris Region, Assistance Publique – Hôpitaux de Paris (AP-HP), Inserm, BioSerenity, Casis, Fealinx and Firalis announced the PACIFIC consortium (Physiopathology, Classification, Innovation in Heart Failure).
PACIFIC aims to give a new definition of heart failure with preserved ejection fraction (HFpEF), a complex and heterogeneous syndrome that lacks a specific diagnostic test. Its objectives:
- understand how patients differ, through a prospective clinical study;
- divide the patient population into more homogeneous subgroups;
- apply machine learning to the data collected;
- develop specific diagnostic tools;
- build an innovation network on HFpEF in France.
The five-year project stems from a 2017 call for projects initiated by Sanofi and Servier with Medicen. AP-HP, promoter of the clinical study, recruits patients in five of its cardiology hospitals, under the coordination of Prof. Jean-Sébastien Hulot at the Hôpital Européen Georges Pompidou.
Firalis, one of the four SMEs in the consortium, provides biomarkers for diagnosis, both soluble and molecular.
Source PACIFIC consortium press release, Paris, 21 January 2019.